Previous 10 | Next 10 |
Strategic investment and partnership brings Spatial’s multiomics platform and seqFISH technology to Fulgent’s comprehensive suite of genomic testing solutions Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a tech...
Full Year 2021 Total Revenue grows 135% year-over-year to $992.6 million; Q4 Revenue totals $251.7 million Full Year 2021 Core Revenue grows 236% year-over-year to $122.6 million; Q4 Core Revenue grows 234% year-over-year to $40.1 million Fulgent Genetics, Inc. (NASDAQ: ...
AAN, ACA, OTCPK:ACLLF, AEM, AEVA, AGI, AHT, ALLO, ALR, AMED, ANSS, ARNA, AZUL, BAND, BBDC, BBWI, BCSF, BHP, BIRD, BKNG, BMA, BMRN, CCRN, CDEV, CHDN, CHK, CLOV, CMLS, CPE, CSV, CTRA, CW, DHC, DK, DKL, EBAY, EFC, OTCPK:EIFZF, EVH, EXR, FBRT, FIVN, FIX, FLGT, FLS, FNF, FRG, FTI, FUBO, GBT, GH, G...
Apple (NASDAQ: AAPL) posts record revenue. Microsoft (NASDAQ: MSFT) makes its intentions clear with respect to its gaming division. Visa (NYSE: V) and American Express (NYSE: AXP) rise on strong results. Tesla (NASDAQ: TSLA) tells Wall Street not to e...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will relea...
Shares of companies that benefited from the pandemic have been crushed in the past few months. That's something shareholders of Fulgent Genetics (NASDAQ: FLGT) have gotten used to. The stock peaked early last year and has been yo-yoing ever since. The ups and downs have depe...
Fulgent has benefited tremendously from the COVID-19 pandemic tailwinds. But, its revenue could be set to decline following a highly successful two years. We believe that management needs to address its long-term operating model with more urgency in its FQ4 earnings call. None...
Shares of Fulgent Genetics (NASDAQ: FLGT) sank 36.5% amid turbulent trading for the broader market in January, according to data from S&P Global Market Intelligence . Both the S&P 500 and the Nasdaq Composite indexes entered into correction territory amid mountin...
Before the pandemic, Fulgent Genetics (NASDAQ: FLGT) was a little-known genetic testing business with grand ambitions but limited means. Since January of 2020, its stock has provided the not-too-shabby return of 385%. Now, with more than $1 billion in trailing 12-month revenue d...
Shares of diagnostic testing company Fulgent Genetics (NASDAQ: FLGT) were up 93% last year, according to S&P Global Market Intelligence . The unpredictability of COVID took shareholders on a journey through several peaks and valleys on the way to that gain. The roller co...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...
2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...